Market Value3,372,652,431
Total Holdings73
File Date2025-02-14
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
PTGX / Protagonist Therapeutics, Inc.
INSP / Inspire Medical Systems, Inc.
OCUL / Ocular Therapeutix, Inc.
BBIO / BridgeBio Pharma, Inc.
MDGL / Madrigal Pharmaceuticals, Inc.
VERV / Verve Therapeutics, Inc.
XNCR / Xencor, Inc.
PODD / Insulet Corporation
VKTX / Viking Therapeutics, Inc.
BNTX / BioNTech SE - Depositary Receipt (Common Stock)
GERN / Geron Corporation
MRVI / Maravai LifeSciences Holdings, Inc.
KRYS / Krystal Biotech, Inc.
SKYE / Skye Bioscience, Inc.
CGON / CG Oncology, Inc.
IRTC / iRhythm Holdings, Inc.
NBIX / Neurocrine Biosciences, Inc.
GKOS / Glaukos Corporation
BRKR / Bruker Corporation
REPL / Replimune Group, Inc.
PEN / Penumbra, Inc.
RGEN / Repligen Corporation
ORKA / Oruka Therapeutics, Inc.
APLS / Apellis Pharmaceuticals, Inc.
CELC / Celcuity Inc.
ARGX / argenx SE - Depositary Receipt (Common Stock)
LXEO / Lexeo Therapeutics, Inc.
BSX / Boston Scientific Corporation
SKIN / SkinHealth Systems Inc.
HLVX / HilleVax, Inc.
ELEV / Elevation Oncology, Inc.
DXCM / DexCom, Inc.
DBVT / DBV Technologies S.A. - Depositary Receipt (Common Stock)
GH / Guardant Health, Inc.
SRPT / Sarepta Therapeutics, Inc.
PCVX / Vaxcyte, Inc.
IRWD / Ironwood Pharmaceuticals, Inc.
CBLL / CeriBell, Inc.
TMO / Thermo Fisher Scientific Inc.
DNTH / Dianthus Therapeutics, Inc.
ARVN / Arvinas, Inc.
XENE / Xenon Pharmaceuticals Inc.
EWTX / Edgewise Therapeutics, Inc.
AVDL / Avadel Pharmaceuticals plc
US40131MAB54 / CONVERTIBLE ZERO
US670704AJ40 / NuVasive, Inc.
JSPR / Jasper Therapeutics, Inc.
US10806XAD49 / BRIDGEBIO PHARMA INC
IMTX / Immatics N.V.
NVRO / Nevro Corp.
NVCR / NovoCure Limited
FNA / Paragon 28, Inc.
US10806XAB82 / Bridgebio Pharma, Inc.
BCAX / Bicara Therapeutics Inc.
RCUS / Arcus Biosciences, Inc.
FDMT / 4D Molecular Therapeutics, Inc.
US232109AD04 / Cutera Inc
CUTERA INC / NOTE 4.000% 6/0 (232109AG3)
DEXCOM INC / NOTE 0.375% 5/1 (252131AM9)
VRDN / Viridian Therapeutics, Inc.
REPLIGEN CORP / NOTE 1.000%12/1 (759916AD1)
AMPHASTAR PHARMACEUTICALS IN / NOTE 2.000% 3/1 (03209RAB9)
AVTE / Aerovate Therapeutics, Inc.
RLAY / Relay Therapeutics, Inc.
LXRX / Lexicon Pharmaceuticals, Inc.
ALEC / Alector, Inc.
ZURA / Zura Bio Limited
KIDS / OrthoPediatrics Corp.
NUVL / Nuvalent, Inc.
CSTL / Castle Biosciences, Inc.
FULC / Fulcrum Therapeutics, Inc.
EXAS / Exact Sciences Corporation
APGE / Apogee Therapeutics, Inc.
US252131AK39 / CONV. NOTE
HROW / Harrow, Inc.
SYRE / Spyre Therapeutics, Inc.
LUNG / Pulmonx Corporation
KNSA / Kiniksa Pharmaceuticals International, plc
DAWN / Day One Biopharmaceuticals, Inc.
US46333XAH17 / CONV. NOTE
ALGN / Align Technology, Inc.
ISRG / Intuitive Surgical, Inc.
CADL / Candel Therapeutics, Inc.
US02081GAB86 / Alphatec Holdings, Inc.
LEGN / Legend Biotech Corporation - Depositary Receipt (Common Stock)
US64049MAB63 / NeoGenomics Inc
TMDX / TransMedics Group, Inc.
CGEM / Cullinan Therapeutics, Inc.
IOVA / Iovance Biotherapeutics, Inc.
ATEC / Alphatec Holdings, Inc.
DYN / Dyne Therapeutics, Inc.
KROS / Keros Therapeutics, Inc.